H
Herbert L. Bonkovsky
Researcher at University of Connecticut
Publications - 234
Citations - 18143
Herbert L. Bonkovsky is an academic researcher from University of Connecticut. The author has contributed to research in topics: Hepatitis C & Cirrhosis. The author has an hindex of 65, co-authored 211 publications receiving 16685 citations. Previous affiliations of Herbert L. Bonkovsky include University of Connecticut Health Center & Carolinas Medical Center.
Papers
More filters
Journal ArticleDOI
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
Ludmila Prokunina-Olsson,Brian Muchmore,Wei Tang,Ruth M. Pfeiffer,Heiyoung Park,Harold Dickensheets,Dianna Hergott,Patricia Porter-Gill,Adam Mumy,Indu Kohaar,Sabrina Chen,Nathan Brand,McAnthony Tarway,Luyang Liu,Faruk Sheikh,Jacquie Astemborski,Herbert L. Bonkovsky,Brian R. Edlin,Brian R. Edlin,Charles D. Howell,Timothy R. Morgan,Timothy R. Morgan,David L. Thomas,Barbara Rehermann,Raymond P. Donnelly,Thomas R. O'Brien +25 more
TL;DR: RNA sequencing in primary human hepatocytes activated with synthetic double-stranded RNA to mimic HCV infection provides new insights into the genetic regulation of HCV clearance and its clinical management.
Journal ArticleDOI
Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States
Naga Chalasani,Robert J. Fontana,Herbert L. Bonkovsky,Herbert L. Bonkovsky,Herbert L. Bonkovsky,Paul B. Watkins,Timothy J. Davern,Jose Serrano,Hongqiu Yang,James Rochon +9 more
TL;DR: This report summarizes the causes, clinical features, and outcomes from the first 300 patients enrolled in a prospective study to recruit patients with suspected idiosyncratic drug-induced liver injury and create a repository of biological samples for analysis.
Journal ArticleDOI
ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Naga Chalasani,Paul H. Hayashi,Herbert L. Bonkovsky,Victor J. Navarro,William M. Lee,Robert J. Fontana +5 more
TL;DR: This ACG Clinical Guideline is presented an evidence-based approach to diagnosis and management of DILI with special emphasis on DILi due to herbal and dietary supplements and DilI occurring in individuals with underlying liver disease.
Journal ArticleDOI
Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study
Naga Chalasani,Herbert L. Bonkovsky,Robert J. Fontana,William M. Lee,Andrew Stolz,Jayant A. Talwalkar,K. Rajendar Reddy,Paul B. Watkins,Victor J. Navarro,Huiman X. Barnhart,Jiezhun Gu,Jose Serrano,Jawad Ahmad,Nancy Bach,Meena B. Bansal,Huiman X. Barnhart,Kimberly L. Beavers,Herbert L. Bonkovsky,Francisco O. Calvo,Charissa Y. Chang,Hari S. Conjeevaram,Gregory E. Conner,Jama M. Darling,Ynto S. de Boer,Douglas T. Dieterich,Frank DiPaola,Francisco A. Durazo,James E. Everhart,Robert J. Fontana,Marwan Ghabril,David Goldstein,Vani Gopalreddy,Priya Grewal,Paul H. Hayashi,Jay H. Hoofnagle,Neil Kaplowitz,Suthat Liangpunsakul,Steven N. Lichtman,Lawrence Liu,Victor Navarro,Joseph A. Odin,Simona Rossi,Mark W. Russo,Thomas D. Schiano,Averell H. Sherker,Raj Vuppalanchi,Paul B. Watkins,Steven Zacks,Amanda Balasco,Kristin Chesney,Audrey Corne,Sherrie Cummings,Gale Groseclose,Alex Hammett,Judy Hooker,Varun Kesar,Sophana Mao,Kenari Marks,Regina McFadden,Yolanda Melgoza,Sherif Mikhail,Susan Milstein,Wendy Morlan,Val Peacock,Nidia Rosado,Tracy Russell,Maricruz Vega,Manisha Verma,Patricia F. Walker,Rachana Yalamanchili,Michelle McClanahan-Crowder,Katherine Galan,Tuan Chau,Kowsalya Ragavan,Hoss Rostami,Carmel Puglisi-Scharenbroich,Rebecca Torrance,Rebekah Van Raaphorst +77 more
TL;DR: In this article, the authors present characteristics and subgroup analyses from the first 1257 patients enrolled in the study, and conclude that there are no differences in outcomes of patients with short vs long latency of DILI.
Journal ArticleDOI
Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease
Anna S. Lok,Leonard B. Seeff,Timothy R. Morgan,Adrian M. Di Bisceglie,Richard K. Sterling,Teresa M. Curto,Gregory T. Everson,Karen L. Lindsay,William M. Lee,Herbert L. Bonkovsky,Jules L. Dienstag,Marc G. Ghany,Chihiro Morishima,Zachary D. Goodman +13 more
TL;DR: It was found that maintenance peginterferon did not reduce the incidence of HCC in the HALT-C cohort, and baseline clinical and laboratory features predicted risk for HCC.